Seminar: Current Issues in Monitoring Clinical Trials with Thomas Fleming, PhD (Boston)

Time & Location

Originally Presented: September 22, 2009 7:30 AM

Presenter(s):

GLG Expert Contributor

Agenda:

Group sequential guidelines
Goals and challenges in monitoring clinical trials
Importance of confidentiality

View Webcasts & Teleconferences in Healthcare

November 17, 2009 | Listen to Archive Teleconference: Cholesterol War – Merck’s Zetia vs. Abbott’s Niaspan (10:15 AM EST / 15:15 GMT)

November 3, 2009Teleconference: Will Benlysta be the Miracle Drug for Lupus? (10:00 AM EST / 15:00 GMT)

October 28, 2009Teleconference: Who Will Win the Anti-Obesity Pill Race? (9:00 AM EST / 13:00 GMT)

October 27, 2009Teleconference: Future of Gaucher Disease Therapies (11:00 AM EST / 15:00 GMT)

October 7, 2009Webcast: How Will Oral Cladribine and FTY-720 Impact the Multiple Sclerosis Market?

August 5, 2009 | View Webcast Webcast: Personalized Medicine Panel (2:00 PM EDT / 11:00 AM PDT / 19:00 BST)

July 23, 2009Webcast: Discerning Hype from Substance in Clinical Trials (11:00 AM EDT / 16:00 BST)

June 12, 2009 | View Webcast GLG Webcast: Pharmacy Trends with Jan Berger, MD – June 12, 2009 at 2:00 PM ET

May 22, 2009 | View Webcast GLG Webcast: Consolidation Trends - China Pharma on May 22, 2009 at 7:30AM ET

May 15, 2009 | View Webcast GLG Webcast: Domestic Healthcare Policy – May 15, 2009 at 2:00 PM ET/11:00 AM PT

April 17, 2009 | View Webcast GLG Webcast: Growth Opportunities for Healthcare Technology Companies

View All Webcasts & Teleconferences in Healthcare

Learn More About GLG Live Meetings

About GLG Live Meetings

A program focused on educating business and investment professionals through seminars on current trends and core concepts in various industries. Detailed workbooks distributed at the Seminars provide educational reference materials for later review. GLG Live Meetings enable clients to increase thier own industry education by proposing new seminar topics or adding agenda terms to currently scheduled seminars.